MN553 Unit 9 Practice
Questions with Solutions
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to: Question
options:
A. A need to monitor drugs metabolized by 2D6 for toxicity
B. Increased dosages needed of drugs metabolized by 2D6, such as the
selective serotonin reuptake inhibitors
C. Decreased conversion of codeine to morphine by CYP 2D6
D. The need for lowered dosages of drugs, such as beta blockers - -B.
Increased dosages needed of drugs metabolized by 2D6, such as the
selective serotonin reuptake inhibitors
- Rifampin is a nonspecific CYP450 inducer that may: Question options:
A. Lead to toxic levels of rifampin and must be monitored closely
B. Cause toxic levels of drugs, such as oral contraceptives, when
coadministered
C. Induce the metabolism of drugs, such as oral contraceptives, leading to
therapeutic failure
D. Cause nonspecific changes in drug metabolism - -C. Induce the
metabolism of drugs, such as oral contraceptives, leading to therapeutic
failure
- Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
Question options:
A. Decreased therapeutic levels of quinidine
B. Increased therapeutic levels of quinidine
C. Decreased levels of a coadministered drug, such as digoxin, that requires
Pglycoprotein for absorption and elimination
D. Increased levels of a coadministered drug, such as digoxin, that requires
Pglycoprotein for absorption and elimination - -D. Increased levels of a
, coadministered drug, such as digoxin, that requires Pglycoprotein for
absorption and elimination
- Warfarin resistance may be seen in patients with VCORC1 mutation,
leading to:
A. Toxic levels of warfarin building up
B. Decreased response to warfarin
C. Increased risk for significant drug interactions with warfarin
D. Less risk of drug interactions with warfarin - -B. Decreased response to
warfarin
- Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing: Question options:
A. Erythromycin
B. Digoxin
C. Cetuximab
D. Rifampin - -C. Cetuximab
- Carbamazepine has a Black Box Warning recommending testing for the
HLA-B*1502 allele in patients with Asian ancestry prior to starting therapy
due to: Question options:
A. Decreased effectiveness of carbamazepine in treating seizures in Asian
patients with the HLA-B*1502 allele
B. Increased risk for drug interactions in Asian patients with the HLA-B*1502
allele
C. Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-
B*1502 Allele
D. Patients who have the HLA-B*1502 allele being more likely to have a
resistance to carbamazepine - -C. Increased risk for Stevens-Johnson
syndrome in Asian patients with HLA-B*1502 Allele
- A genetic variation in how the metabolite of the cancer drug irinotecan SN-
38 is inactivated by the body may lead to: Question options:
Questions with Solutions
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to: Question
options:
A. A need to monitor drugs metabolized by 2D6 for toxicity
B. Increased dosages needed of drugs metabolized by 2D6, such as the
selective serotonin reuptake inhibitors
C. Decreased conversion of codeine to morphine by CYP 2D6
D. The need for lowered dosages of drugs, such as beta blockers - -B.
Increased dosages needed of drugs metabolized by 2D6, such as the
selective serotonin reuptake inhibitors
- Rifampin is a nonspecific CYP450 inducer that may: Question options:
A. Lead to toxic levels of rifampin and must be monitored closely
B. Cause toxic levels of drugs, such as oral contraceptives, when
coadministered
C. Induce the metabolism of drugs, such as oral contraceptives, leading to
therapeutic failure
D. Cause nonspecific changes in drug metabolism - -C. Induce the
metabolism of drugs, such as oral contraceptives, leading to therapeutic
failure
- Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
Question options:
A. Decreased therapeutic levels of quinidine
B. Increased therapeutic levels of quinidine
C. Decreased levels of a coadministered drug, such as digoxin, that requires
Pglycoprotein for absorption and elimination
D. Increased levels of a coadministered drug, such as digoxin, that requires
Pglycoprotein for absorption and elimination - -D. Increased levels of a
, coadministered drug, such as digoxin, that requires Pglycoprotein for
absorption and elimination
- Warfarin resistance may be seen in patients with VCORC1 mutation,
leading to:
A. Toxic levels of warfarin building up
B. Decreased response to warfarin
C. Increased risk for significant drug interactions with warfarin
D. Less risk of drug interactions with warfarin - -B. Decreased response to
warfarin
- Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing: Question options:
A. Erythromycin
B. Digoxin
C. Cetuximab
D. Rifampin - -C. Cetuximab
- Carbamazepine has a Black Box Warning recommending testing for the
HLA-B*1502 allele in patients with Asian ancestry prior to starting therapy
due to: Question options:
A. Decreased effectiveness of carbamazepine in treating seizures in Asian
patients with the HLA-B*1502 allele
B. Increased risk for drug interactions in Asian patients with the HLA-B*1502
allele
C. Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-
B*1502 Allele
D. Patients who have the HLA-B*1502 allele being more likely to have a
resistance to carbamazepine - -C. Increased risk for Stevens-Johnson
syndrome in Asian patients with HLA-B*1502 Allele
- A genetic variation in how the metabolite of the cancer drug irinotecan SN-
38 is inactivated by the body may lead to: Question options:
